New York, New York, September 7, 2023–Click Therapeutics today announced the execution of a new collaboration agreement with Indivior for the development and commercialization of prescription digital therapeutics to treat substance use disorders, beginning with Opioid Use Disorder (OUD). Through a novel mobile application, CT-102, the collaboration aims to help close major gaps in OUD treatment, such as access to high-quality, personalized psychosocial treatment.

Designed to work alongside pharmacotherapy, CT-102 will combine evidence-based behavioral therapy with tailored neuromodulatory interventions using Click’s AI-enabled platform to deliver personalized care to each patient. This collaboration will build on Indivior’s expertise in the commercialization of innovative treatments for substance use disorders and Click Therapeutics’ substantial real-world experience engaging patients seeking help with addiction.

Click will lead development with an iterative, patient-centric and evidence-based approach that leverages the company’s end-to-end development capabilities and proprietary technology platform. This phased process is designed to ensure CT-102 will be launched as a best-in-class therapy supported by compelling evidence that will drive broad access and adoption. These efforts will start with a preliminary exploration phase to explore and define the product scope that will best match the needs of patients, providers and payers. More information will be available following completion of the exploration phase in 2024.

This is the fourth major co-development and commercialization collaboration to be announced that is based on Click Therapeutics’ clinically validated platform. Under the terms of the collaboration agreement, Click Therapeutics will be responsible for all technical and clinical development activities, as well as regulatory filings and technical services through commercialization. In return, Indivior will receive a global license to commercialize CT-102. Click Therapeutics will receive upfront license and early development payments, and is eligible to receive additional regulatory and commercial milestones plus double-digit royalties on global sales. In addition, there is an opportunity for a higher total deal value based on the potential development of additional products in the future.

Click Therapeutics, Inc. develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. We are expanding the possibilities of medicine with Digital Therapeutics™ that combine clinical science with the power of software to create a new way to treat disease.  

Operating at the intersection of biology and technology, we use a proprietary platform-based approach to therapeutic development that leverages patient-centric design principles and innovative AI-based technologies to deliver a unique combination of engagement and clinical outcomes, consistently. Digital therapeutics on Click’s platform are regulated, clinically validated prescription mobile applications that can address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. 

Click Therapeutics, in collaboration with Otsuka, developed the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms, Rejoyn™. In October 2024, in response to FDA guidance on prescription drug use-related software (PDURS), we launched Click SE™ to extend our digital therapeutics platform and expertise to the development of software-enhanced drug™ therapies that combine software with pharmacotherapy to offer added clinically meaningful benefit to patients.

Our commitment to advancing digital medicine means we continually improve our platform technologies, ensuring we stay at the forefront of cognitive, behavioral, and neuromodulatory therapeutic innovation, to achieve the best possible outcomes for patients. Our diverse team of innovators—spanning clinicians, researchers, technologists, designers and more—works together to create cutting-edge digital therapeutics, united in the mission to transform patient care. For more information, visit www.clicktherapeutics.com and connect with us on LinkedIn.